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Abstract
Purpose: To analyze the differences between the intensity-modulated radiotherapy (IMRT), single/partial-arc volumetric
modulated arc therapy (SA/PA-VMAT) techniques in treatment planning for locally advanced lung cancer.
Materials and methods: 12 patients were retrospectively studied. In each patient’s case, several parameters were
analyzed based on the dose-volume histograms (DVH) of the IMRT, SA/PA-VMAT plans respectively. Also, each plan
was delivered to a phantom for time comparison.
Results: The SA-VMAT plans showed the superior target dose coverage, although the minimum/mean/maximum
doses to the target were similar. For the total and contralateral lungs, the higher V5/10, lower V20/30 and mean lung
dose (MLD) were observed in the SA/PA-VMAT plans (p < 0.05, respectively). The PA-VMAT technique improves the
dose sparing (V20, V30 and MLD) of the controlateral lung more notably, comparing to those parameters of the
IMRT and SA-VMAT plans respectively. The delivered monitor units (MUs) and treatment times were reduced
significantly with VMAT plans, especially PA-VMAT plans (for MUs: mean 458.3 vs. 439.2 vs. 435.7 MUs, p < 0.05 and
for treatment time: mean 13.7 vs. 10.6 vs. 6.4 minutes, p < 0.01).
Conclusions: The SA-VMAT technique achieves highly conformal dose distribution to the target. Comparing to the
IMRT plans, the higher V5/10, lower V20/30 and MLD were observed in the total and contralateral lungs in the VMAT
plans, especially in the PA-VMAT plans. The SA/PA-VMAT plans also reduced treatment time with more efficient dose
delivering. But the clinical benefit of the VMAT technique for locally advanced lung cancer needs further investigations.
Keywords: Lung cancer, Intensity-modulated radiotherapy, Volumetric modulated arc therapy, Target dose distribu-
tion, Normal tissue toxicity
Introduction
VMAT is a new form of IMRT, which allows irradiation
with the simultaneously changing gantry position, dose
rate and multileaf-collimator (MLC) position [1]. Recently,
several studies have been published showing the potential
of the VMAT techniques to reduce the treatment time
without compromising plan quality compared to IMRT in
radiotherapy planning for different cancer types, including
lung cancers [2-6], prostate cancer [7] and annal cancer
[8]. In practice, the VMAT optimization depends on the
choice of various plan parameters, such as the number of
arcs, the delivery time or the gantry angle spacing between
subsequent control points.
A few studies investigated the clinical and dosimetric
advantages of the VMAT technique in treatment for lung
cancer presently. Bedford et al. reported the first lung
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cancer case treated with VMAT [2]. Scorsetti et al.
reported the acute toxicity, initial outcome results and
planning parameters of 24 patients with the large-volume
non-small cell lung cancer (NSCLC) treated with VMAT,
while no dosimetric comparison was described [3]. For
peripheral lung cancers, McGrath et al. concluded that
VMAT allows delivering of the hypofractionated doses
much faster than the conventional stereotactic body radio-
therapy (SBRT), with the additional advantage for the tar-
get dose conformity [4]. Cao et al. compared the plan
quality of intensity-modulated arc therapy (IMAT) and
helical tomotherapy, and stated that IMAT can provide
the plan qualities comparable to that of the helical
tomotherapy for most cases [5]. Very recently, Holt’s team
found that a coplanar VMAT for SBRT for early-stage
lung cancer achieved a plan quality and skin dose levels
better than those coplanar IMRT plans and reduced treat-
ment time at most by 70% [6]. To our knowledge, no dosi-
metric evaluation had been reported between IMRT and
VMAT for locally advanced lung cancer yet.
Up to now, the issues existed that whether or not a sin-
gle arc VMAT could achieve dose distributions compar-
able to IMRT plan. One study stated that two or more
arcs are required in treatment of the complex-shaped tar-
get volumes [9], whereas Bertelsen et al. [10] found that a
single arc is sufficient to achieve plan quality similar to
IMRT. Also, data from Guckenberger et al. indicated the
complexity of the target volume determined whether sin-
gle arc VMAT was equivalent to IMRT [11]. In addition,
McGrath’s study showed the significant lung dose reduc-
tion in VMAT plans appling a partial arc range of 180°
coincide with tumor location [4]. As it could improve
lung dose sparing and reducing treatment time, the pos-
sible and potential benefits of PA-VMAT in treatment
for central and bulky lung cancer are not clear so far.
Here, we reported our planning analysis for the locally
advanced lung cancers in these two fields: comparing
the dosimetric parameters derived from IMRT and SA/
PA-VMAT plans and evaluating treatment delivery effi-
ciency and treatment times.
Materials and methods
This study was conducted between October 2010 and
March 2011. Totally, 12 patients with pathologically
confirmed locally advanced NSCLC were randomly
selected for analysis. The patient characteristics were
listed in Table 1. All patients were staged according to
the modified 1997 AJCC staging system [12]. Permission
to conduct the study was granted by the Research Ethics
Board of the University Health Network.
Target delineation and dose prescription
Patients were simulated supine in an individualized
thermoplastic mask with their arms raised above the
head on a lung board designed to support the elbows.
All of the computed tomograph (CT) images (Sie-
mens, Somatom Plus 4) of the patients were trans-
ferred to and registered in the treatment planning
system (TPS).
The gross tumor volume (GTV) was defined as the
macroscopically identifiable tumor including lymph
nodes with a diameter more than 1 cm on CT. The
clinical tumor volume (CTV) enclosed the GTV with an
8 mm margin towards lung tissue and a 5 mm margin
around affected lymph nodes. For the planning target
volume (PTV), the 10 or 15 mm margin was added iso-
tropically to the CTV if the tumor location is superior
or inferior lobe. The organs at-risk (OARs) included:
lungs (ipsilateral and contralateral), spinal cord, esopha-
gus and heart. The planning organ at-risk volumes
(PRVs) were extended as 5 mm to the esophagus and
the spinal cord, respectively; all expansion was not
applied to the lungs. The dose-volume constraints for
the lungs were set as follows: V20 < 30%, V30 < 20% and
mean lung dose < 20 Gy. The maximum dose of 45 Gy
was allowed to the spinal cord (PRV). In addition, the
plan optimization was performed with the aim to keep
the esophagus PRV dose of 55 Gy (V55) to 30% of the
organ volume and the heart PRV dose of 40 Gy (V40) to
50% of the organ volume.
All generated plans for each patient consisted of 68
Gy to be delivered to PTV in 34 fractions. The objective
of planning was to deliver the prescribed dose to at least
95% of the PTV with a dose range not exceeding -10%
and +15% of the prescribed dose. All plans were gener-
ated for the Elekta Beam Modulator (Elekta Oncology
Systems, Crawley, UK).
Table 1 Basic and clinical characteristics of the studied















Total lung volume (cm3)
Median 3525.7
Range 2676.2-4810.5
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Treatment planning and optimizing
IMRT
The IMRT optimization was performed by appling
Direct Machine Parameter Optimization (DMPO) algo-
rithm in our treatment planning system (Pinnacle3, Phi-
lips Radiation Oncology Systems, Fitchburg, USA) as
described previously [13]. For each plan, an average of
40 segments were used based on 5 (whose angels were
216°, 288°, 0°, 72°, 144°, respectively) or 7 (whose angels
were 204°, 256°, 308°, 0°, 52°, 104°, 156°, respectively)
coplanar beams with the angles depending on the tumor
location (Figure 1a). In the plan generation, the maxi-
mum iterations in the plan optimizing were 40, and the
maximum number of all segments in one plan was
restricted to 100. There is no limitation to the MUs per
segment. Plans were generated for the Elekta Beam
Modulator with 6-MV.
SA-VMAT
The VMAT planning was done applying the SmartArc
planning algorithm in Pinnacle3® 9.0 (research version,
Philips Radiation Oncology Systems, Fitchburg, USA).
The optimiser (single arc) was constrained to use one
single 360° arc which consisted of 90 control points.
The arc was represented by 89 beams each separated by
4° (Figure 1b), which started and ended at 180°, respec-
tively. The accelerator used automatic dose rate selec-
tion which ensures that the maximal possible dose rate
was chosen for each individual segment of the arc. The
initial step is performed based on SmartArc algorithm
to obtain the optimal modulated fluence. In the second
step, the segments are optimized based on the small
ares of targets with insuffient irradiation dose using the
same algorithm. Plans were generated with 6-MV either.
PA-VMAT
The plans were optimized in the same planning system
mentioned above. A 180-200° partial arc was generated
for standardization across the studied cases with the
range coinciding with the tumor location while avoiding
as much of the contralateral lung as possible, which
started between 170°-180° and ended between 0°-10°.
The arc was represented by 44-49 beams each separated
by 4° either (Figure 1c).
Evaluation of the DVH-based parameters
The conformity index (CI) and homogeneous index (HI)
for PTV was calculated as we described previously [13].
The CI was defined as cover factor (the percentage of
the PTV volume receiving 68 Gy) ×spill factor (the
volume of the PTV receiving the 68 Gy relative to the
total prescription dose-volume). The HI was defined the
minimum dose in 5% of the PTV (D5)/munimum dose
in 95% of the PTV (D95).
Other parameters were collected from the DVH of
these generated plans and compared to each other
respectively, including V5/10/20/30 (the percentage
volumes which received 5, 10, 20 and 30 Gy respec-
tively) of lungs, average dose (Dmean) of lungs/heart/
esophagus, V30 and V40 (the percentage volumes which
received 30 and 40 Gy respectively) of heart, Dmax and
D5 (the maximum dose and the dose that 5% volume
of spinal cord received) of spinal cord and V55 (the
percentage volumes which received 55 Gy) of
esophagus.
All plans were transferred to our treatment system for
time comparison.
Statistical analysis
The collected data were analyzed applying “mean ±
standard deviation (SD)” with SPSS software (version
13.0, Chicago, USA). Based on the Wilcoxon’s signed
rank test, a value of p < 0.05 was considered to have sta-
tistical significance.
Results
Totally, 36 plans are generated following the protocol
and analyzed. The transverse sections of the representa-
tive plans with irradiation dose curves of one patient are
shown in Figure 2. Obviously, lower dose irradiated to
the larger volume of the total lungs were observed in
SA/PA-VMAT plans, respectively.
Figure 1 Representative beam arrangements (a: IMRT, b: SA-VMAT and c: PA-VMAT). The green, blue and yellow arrows indicate the start
point, end point and one control point in SA/PA-VMAT plans, respectively.
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The evaluation of the DVH-based parameters of the
PTV is shown in Table 2. The maximum, minimum and
average dose of the PTV are similar between IMRT and
SA/PA-VMAT plans respectively, with no statistical sig-
nificance (p > 0.05). While, the average CI in SA-VMAT
plans (0.68 ± 0.06) is significantly better than those
indexes in plans of IMRT (0.62 ± 0.07) and PA-VMAT
(0.62 ± 0.06), respectively (p < 0.05). Also, the average
HI in SA-VMAT plans (1.11 ± 0.04) is better than those
in IMRT (1.15 ± 0.04) and PA-VMAT plans (1.15 ±
0.04) respectively, with the statistical significances (p <
0.05).
Table 3 shows the comparisons of the DVH-based
parameters of the lungs in the present study. Comparing
to the IMRT plans, the SA/PA-VMAT plans show
advantages in dose sparing of the total and controlateral
lungs, respectively (all p < 0.05). But IMRT plans show
the lower V5 and V10 of the total (50.6 ± 10.6% and 40.2
± 7.2%) and contralateral lungs (44.7 ± 10.7% and 32.1 ±
7.1%), comparing to the SA/PA-VMAT plans respec-
tively (all p < 0.05). Although the SA/PA-VMAT plans
showing a trend to increaseing the volume received
irradiation, no siginificant difference was observed in the
comparisons between the parameters of the ipsilateral
lungs in this study (all p > 0.05). Especially, the PA-
VMAT technique reduced the V20 (7.5 ± 2.2), V30 (1.3 ±
0.6) and MLD (7.8 ± 1.0) of the contralateral lungs sig-
nificantly, comparing to those parameters of the SA-
VMAT plans (p = 0.049, 0.048 and 0.038, respectively).
The comparisons of the parameters of other OARs in
present study are also shown in Table 3. The SA/PA-
VMAT techniques do not show advantages in dose
sparing of the other evaluating OARs (Dmax and D5 to
the spinal cord; V30, V40 and Dmean to the heart; V55
and Dmean to the esophagus). These differences between
the IMRT and SA/PA-VMAT plans are not statistically
significant respectively (all p > 0.05).
Comparing to the IMRT plans (13.7 ± 2.6 minutes),
the SA/PA-VMAT plans reduce the treatment time
(10.6 ± 1.8 and 6.4 ± 1.5 minutes, respectively) signifi-
cantly as expected (all p < 0.01). Also, we found that the
SA/PA-VMAT techniques are more efficient in dose
delivery during treatment than that of the IMRT plans
(439.2 ± 22.5/435.7 ± 25.3 vs. 458.3 ± 21.9 MUs)
(shown in Table 4).
Discussion
As mentioned earlier, the implementation of the VMAT
technique gains its value in the treatment for different
kinds of the solid tumors, even the tumor targets shaped
complex, compared to the conformal radiation therapy
(CRT) and IMRT. In present study, we provided in
details the dosimetric differences between IMRT and
the SA/PA-VMAT plans in the treatment for locally
advanced lung cancer.
At present, with the introduction of involved-field
radiation therapy (IFRT) and omission of elective nodal
irradiation (ENI) in treatment for locally advanced
NSCLC, the PTVs of stage III cases, especially IIIB
(involving the bilateral mediastinum) are somewhat
complex and more like a “dumb bell”. Referring to the
suggestion from Guckenberger et al. [11], the SA-
VMAT plans were generated and compard to IMRT
Figure 2 Transverse sections of the representative plans of one patient with the irradiation isodose curves (a: IMRT, b: SA-VMAT and
c: PA-VMAT). The pink, yellow, blue and red lines represent the dose curves of 10, 20, 40 and 64.6 (95% of the prescription dose) Gy,
respectively.
Table 2 Comparisons of the DVH-based parameters of








































a: compared with the parameters of IMRT; b: compared with the parameters of
IMRT; c: compared with the parameters of SA-VMAT; d: the minimum,
maximum and mean irradiation dose of the PTV, respectively; e: conformity
index, calculated with the fomula as we applied previously [13]; f:
homogeneous index, calculated with the fomula: “HI = D5/D95“;
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plans. Under the consideration of reducing more treat-
ment time, we also designed the case-individualized PA-
VMAT plans for evaluation according to the location of
the targets. As expected, our data indicate that in treat-
ment planning for locally advanced lung cancer, a single
arc VMAT plan achieve superior dose covarage for PTV
(the CI and HI are all better, p < 0.05), even a partial
arc VMAT could achieve such dose distribution com-
pared to IMRT plans. This was also in a line with the
study by Scorsetti et al. [3], the VMAT technique
allowed them to achieve the most objectives on target
volumes and OARs in radiation therapy for stage III
NSCLC in practice. Recently, Yang et al. designed and
generated a trajectory-based, noncoplanar subarc for
VMAT delivery [14]. They found that after the plan
optimization, the trajectory-based VMAT technique
showed improved target dose conformality and reduced
irradiation dose for OARs, compared to the standard
VMAT and IMRT in treating central nervous system
tumors. And the potential advantages of such technique
Table 3 Comparisons of the DVH-based parameters of the OARsa in present study (n = 12)
IMRT SA-VMAT PA-VMAT
mean ± SD mean ± SD p valueb mean ± SD p valuec p valued
Total lungs
V5
e (%) 50.6 ± 10.6 59.7 ± 10.8 0.048 59.3 ± 9.1 0.042 0.923
V10
e (%) 40.2 ± 7.2 46.9 ± 8.3 0.046 46.4 ± 7.3 0.048 0.877
V20
e (%) 25.7 ± 5.7 21.1 ± 4.8 0.044 20.3 ± 4.4 0.016 0.675
V30
e (%) 15.8 ± 3.4 12.9 ± 3.2 0.043 12.5 ± 3.2 0.023 0.876
MLDf (Gy) 14.4 ± 2.3 12.5 ± 2.2 0.047 12.3 ± 2.2 0.028 0.785
Contralateral lungs
V5 (%) 44.7 ± 10.7 55.2 ± 11.9 0.033 53.8 ± 9.4 0.038 0.752
V10 (%) 32.1 ± 7.1 39.4 ± 9.8 0.048 38.5 ± 7.3 0.041 0.801
V20 (%) 13.8 ± 4.4 10.2 ± 4.1 0.046 7.5 ± 2.2 < 0.01 0.048
V30 (%) 3.3 ± 1.9 2.0 ± 1.0 0.048 1.3 ± 0.6 < 0.01 0.049
MLD (Gy) 9.6 ± 1.2 8.7 ± 1.0 0.038 7.8 ± 1.0 < 0.01 0.038
Ipsilateral lungs
V5 (%) 67.6 ± 10.5 68.9 ± 11.8 0.778 72.4 ± 13.7 0.346 0.052
V10 (%) 56.8 ± 9.1 57.3 ± 9.7 0.898 61.1 ± 11.5 0.321 0.167
V20 (%) 43.9 ± 5.8 45.2 ± 6.3 0.604 43.1 ± 5.2 0.725 0.383
V30 (%) 29.8 ± 1.2 29.9 ± 1.4 0.853 29.5 ± 1.2 0.547 0.460
MLD (Gy) 18.8 ± 2.98 20.2 ± 2.9 0.264 18.3 ± 2.8 0.728 0.141
Spinal cord
Dmax
f (Gy) 43.0 ± 2.5 41.6 ± 2.5 0.194 42.5 ± 2.4 0.603 0.404
D5
g (Gy) 40.3 ± 3.8 39.8 ± 3.9 0.711 40.1 ± 3.9 0.891 0.837
Heart
V30
e (%) 20.9 ± 5.7 20.8 ± 5.8 0.973 21.2 ± 6.3 0.894 0.870
V40
e (%) 14.6 ± 5.5 13.4 ± 5.5 0.595 15.0 ± 5.9 0.859 0.788
Dmean
f (Gy) 14.8 ± 7.7 14.4 ± 7.4 0.915 15.1 ± 7.5 0.903 0.818
Esophagus
V55
e (%) 12.4 ± 7.3 12.3 ± 7.5 0.971 13.6 ± 8.3 0.707 0.685
Dmean
f (Gy) 22.4 ± 5.6 21.9 ± 5.2 0.811 23.7 ± 6.3 0.609 0.455
a: organs at-risk; b: compared with the parameters of IMRT; c: compared with the parameters of IMRT; d: compared with the parameters of SA-VMAT; e: the volume
of the lung that received the 5, 10, 20, 30, 40 and 55 Gy irradiation dose, respectively; f: the maximum or mean irradiation dose that the lung, spinal cord, heart
and esophagus received, respectively; g: the irradiation dose that the 5% volume of the spinal cord received.
Table 4 Comparisons of other evaluated parameters in present study (n = 12)
IMRT SA-VMAT PA-VMAT
mean ± SD mean ± SD p valuea mean ± SD p valueb p valuec
Delivery timed 13.7 ± 2.6 10.6 ± 1.8 < 0.01 6.4 ± 1.5 < 0.01 < 0.01
Treatment
Efficiencye
458.3 ± 21.9 439.2 ± 22.5 0.030 435.7 ± 25.3 0.047 0.732
a: compared with the parameters of IMRT; b: compared with the parameters of IMRT; c: compared with the parameters of SA-VMAT; d: presented as minutes; e:
presented as monitor units (MUs);
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in radiotherapy for NSCLC need further dosimetric
evaluation.
The radiation-induced pneumonitis (RIP) is one of the
most common side-effects in CRT for thoracic malig-
nancies. This complication, which has a considerable
impact on patient morbidity and sometime leads to
death, is strongly correlated with the irradiation dose
delivered to the lungs. A number of studies have indi-
cated that the dosimetric parameters from the lung
DVH are important in predicting RIP risk [15-18]. Sev-
eral studies showed that MLD approach seems to pro-
vide the most consistent results in terms of increasing
RIP rate with increasing MLD, but some stated not
[15,16]. And many investigations indicated that the V20
and V30 also were predictive factors of RIP, especially of
the severe grade (≥ 2) [17,18]. Our study found that the
V20, V30 and MLD of the total and contralateral lungs
were reduced significantly in the SA/PA-VMAT plans
than those in IMRT plans respectively (p < 0.05, as
shown in table 3). This founding is correlated with the
study of McGrath et al. among lung cancer patients [4],
and indicats the possible dosimetric advantages of
VMAT in treatment for central and bulky lung cancers.
Furthermore, we noticed that the PA-VMAT technique
results in significantly better V20, V30 and MLD for the
contralateral lung when compared to the SA-VMAT
technique; while the total lung and ipsilateral lung para-
meters were not found to be different. Although we rea-
lized that SBRT regimens could not easily be compared
with conventional CRT regimens, this findings is still
partly correlated the results from Holt et al. [6], indicat-
ing the potential value of the PA-VMAT technique in
treatment for the locally advanced lung cancers.
On the other hand, we noticed that the V5 and V10 of
the total and contralateral lungs in the SA/PA-VMAT
plans were higher than those of IMRT plans, respec-
tively (p < 0.05). According to the Schallenkamp’s report
of a 92-patient cohort, the V10/13/15 was also signifi-
cantly correlated to the RIP either [19]. Wang et al.
found that V5 of both lung lobes was the only parameter
predicting the RIP (≥ grade 2) in NSCLC patients trea-
ted with definitive concurrent chemoradiotherapy [20].
In a study from Netherlands, Palma et al. reported a
case of the “Severe’’ radiological pneumonitis 3 months
after SBRT using VMAT and its corresponding treat-
ment plan [21]. Although they concluded that severity
and patterns of the RIP were similar, the VMAT techni-
ques still obviously delivered low irradiation dose to a
larger volume of lung than IMRT did. From this point
of view, the VMAT technique might increase the RIP
rate more than the IMRT dose.
The DVH-based parameters of the ipsilateral lung
were similar in the IMRT and VMAT plans as displayed
in table 3. We could not add the V5-15 and V20/30 of the
ipsilateral lung as the predictive factors for the RIP fol-
lowing the investigations from Yorke et al. and Ramella
et al. [22,23]. As it reduced middle dose volume but
increasing low dose volume of the total and contralat-
eral lungs, the conclusion could not be easily obtained
that the SA/PA-VMAT techniques had the dosimetric
advantages for locally advanced lung cancer from the
present study.
In our study, we did not find significant differences in
dose sparing of other OARs (spinal cord, heart and eso-
phagus) between the IMRT and SA/PA-VMAT plans in
treatment for locally advanced lung cancers.
Beside the dosimetric analysis, similar with other stu-
dies mentioned above [3,4,6,9-11], less treatment time
was observed in plans delivering using the SA/PA-
VMAT techniques. This would be another advantage of
the VMAT technique: enhancing patient satisfaction
and comfort and reducing intrafraction variation. It
might potentially help patients tolerate a whole treament
procedure, particularly those sick or painful cases. Also
in a line with other studies, we observed that the SA/
PA-VMAT plans achieved the comparable dose distribu-
tion of the targets with more less MUs, compared to
IMRT technique (as shown in table 4).
To our knowdge, the applications of several other
techniques that might be helpful to reduce the RIP in
radiotherapy for locally advanced lung cancer, including
the set-up correction with cone beam CT scan and the
active breathing control during simulation and treat-
ment. In present study, we only indicated the dosimetric
advantages and disadvantages of the VMAT techniques
in treatment for locally advanced lung cancers, com-
pared with the IMRT technique. Even only 18% grade 1
and 9% grade 2 acute RIP were observed in 24 patients
with large-volume NSCLC after VMAT treatment [3],
the potential value of the VMAT techniques for central
and bulky lung cancers needs more clinical
investigations.
Conclusions
In this dosimetric and efficiency analysis, the SA-VMAT
plans show more optimal target coverage. Compared to
the IMRT plans, the VMAT plans reduce the V20/30 and
MLD but increase the V5/10 of the total and contralat-
eral lungs. The PA-VMAT technique shows more lung
dose sparing of the contralateral lung. With more effi-
ciency, VMAT plans reduce the treatment time signifi-
cantly. But studies are warranted to evaluate the clinical
benefits of the VMAT in treatment for patients with
locally advanced NSCLC in future.
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